Custirsen (OGX-011/TV-1011), a second-generation antisense oligonucleotide that reduces clusterin production, is under investigation with chemotherapy in prostate and lung cancer. This meta-analysis evaluated the population pharmacokinetics (PK) of custirsen in cancer patients and healthy subjects.
Introduction
Custirsen (OGX-011/TV-1011), a second-generation antisense oligonucleotide that reduces clusterin protein production, is under investigation with chemotherapy in patients with solid tumours. Clusterin is a cytoprotective chaperone protein that is overexpressed in many malignancies, including prostate, breast, ovarian, non-small cell lung (NSCL), colon, kidney, bladder and pancreatic [1] [2] [3] [4] [5] cancers. Forced overexpression of clusterin in preclinical cancer models confers resistance to radiation, hormone-and chemotherapy, whereas inhibition of clusterin expression enhances apoptotic death from these treatment modalities [6] [7] [8] [9] . Based on preclinical and clinical evidence suggesting clusterin as an anti-apoptotic protein, inhibition of its expression by custirsen may lower the apoptotic threshold and therefore sensitize resistant cancer cells to chemotherapeutic drugs.
Custirsen is a 21-mer containing a phosphorothioate (PS) backbone and 2 0 -O-methoxyethyl (2 0 -MOE) modification to the ribose moiety on the flanking four nucleotides on either end of the molecule. This modification enhances binding to the target mRNA and provides an increased resistance to nuclease-mediated degradation, resulting in prolonged tissue half-life and reduced dose frequency compared with firstgeneration antisense oligonucleotides [10] [11] [12] . Custirsen has been administered as single or repeated doses of up to 640 mg via intravenous infusion to over 850 patients in 10 completed studies, including three Phase 1 studies, one Phase 1/2 study, four other Phase 2 studies and two Phase 3 studies. The majority of the patients in these completed studies had either prostate or lung cancer. In addition, custirsen was administered to approximately 100 healthy subjects in three completed Phase 1 studies.
Noncompartmental pharmacokinetic (PK) analysis demonstrated that following intravenous administration, plasma custirsen concentrations peak at the end of infusion and then decay in a multi-exponential fashion with a rapid initial distribution phase followed by a slow terminal elimination phase (t 1/2 of about 30-60 h). Custirsen extensively distributes into tissues as suggested by the large volume of distribution (approximately 100 l). Plasma clearance is relatively low (approximately 2.5 l h À1 ). Mean maximal plasma concentration (C max ) and area under plasma concentration curve (AUC) of custirsen increase linearly with increasing dose (40-640 mg) and no plasma accumulation is observed upon repeated weekly administration [13] [14] [15] . The kidney and liver are major target organs for custirsen tissue distribution based on preclinical data. Internalized molecules are metabolized by endo-and exonucleases to lower molecular weight fragments, which are then excreted in urine, and to a lesser extent in faeces. Pharmacokinetic findings were similar in both healthy volunteers and cancer patients (unpublished data).
The primary objective of this analysis was to develop a population PK model of custirsen after intravenous administration in cancer patients and healthy subjects, as well as to identify covariates which might contribute to the interindividual variability (IIV) in custirsen PK.
Patients and methods

Study design and analysis population
The population PK analysis was performed using plasma concentration data from five Phase 1 studies, one Phase 1/2 study, and one Phase 3 study of custirsen in two stages. In the first stage prior to the availability of the Phase 3 data, an interim analysis was conducted using all available relevant data from four Phase 1 or 1/2 studies -three studies in cancer patients (OGX-011-01, OGX-011-02 and OGX-011-05) and one study in healthy subjects (TV1011-DDI-102). In the second stage, the analysis population was enriched with additional data from two additional Phase 1 studies in healthy subjects (TV1011-PD-107 and TV1011-TQT-108) and one Phase 3 study in cancer patients (SYNERGY: OGX-011-11). Three of the Phase 1 studies were multiple-dose studies (40-640 mg) in combination with neoadjuvant hormonal therapy or chemotherapy in patients with prostate cancer, NSCL cancer, or other types of solid tumours. The remaining three Phase 1 studies were either single-or multiple-dose studies (320-640 mg) in healthy volunteers. The Phase 3 study was a multiple-dose study (640 mg) in combination with docetaxel and prednisone in metastatic castration-resistant prostate cancer (mCRPC) patients. The number of subjects, doses, populations and PK sampling times for each study are presented in Table S1 .
Custirsen was administered as a 2-h intravenous infusion in all studies. An intensive PK sampling scheme was utilized in all Phase 1 studies, whereas a sparse sampling scheme was employed in the Phase 3 study, with only a subset of subjects having intensive PK sampling.
All protocols and consent forms were reviewed and approved by the institutional review boards for each of the study sites, and all subjects provided signed consent. Studies were registered and approved by the respective institutional review boards of the participating centres.
Bioanalytical methods
Plasma concentrations of custirsen were determined using validated hybridization-dependent enzyme-linked immunosorbent assays (ELISA)/cutting. For studies OGX-011-01, OGX-011-02 and OGX-011-05, a method previously described by Chi et al. with a validated range of 3.114 to 38.929 ng ml À1 was used [13] . For studies TV1011-DDI-102, TV1011-PD-107, TV1011-TQT-108 and OGX-011-11, an assay with a validated range of 2.94-36.75 ng ml À1 was developed.
A summary of the assay performance for the studies included in the population PK analysis is shown in Table S2 . Quality control (QC) samples prepared at three different analyte concentrations were analysed with each batch of samples against separately prepared calibration standards.
For the analysis to be acceptable, no more than one-third of the QC results were to deviate from the nominal concentration by more than 20%, and at least 50% of the results from each QC concentration had to be within 20% of nominal. Briefly, custirsen in the plasma was hybridized to a cutting probe that contained the complementary sequence of the antisense oligonucleotide and labelled with biotin at the 5 0 end and with digoxigenin at the 3 0 end. The cutting probecustirsen complex was immobilized to neutravidin-coated plates and nuclease was added to cleave the unhybridized probe. The digoxigenin label on the probe was bound by an anti-digoxingenin IgG conjugated to alkaline phosphatase (ALP). After addition of a fluorogenic substrate, the fluorescence intensity was measured using a fluorescence plate reader.
Population pharmacokinetic analysis
The population PK models were developed using a nonlinear mixed effects modelling approach using the first-order conditional estimation method with interaction (FOCEI) of NONMEM software (version 7.1.2 and above; ICON, Ellicott City, Maryland, USA) [16] to describe the population variability in custirsen PK and the relationship between PK parameters and potential explanatory covariates (e.g., age, weight, gender). Development of the population PK model consisted of building an interim model including covariates using an interim dataset (96 subjects, studies OGX-011-01, OGX-011-02, OGX-011-05 and TV1011-DDI-102); the final model was evaluated and updated with data from an additional 535 subjects from three studies (TV1011-PD-107, TV1011-TQT-108 and OGX-011-11 [including the OGX-011-11SP sub-study]). Structural model selection was data driven, based on goodness of-fit plots (e.g., observed vs. predicted concentration, conditional weighted residual vs. predicted concentration or time, histograms of individual random effects), successful convergence, plausibility and precision of parameter estimates, and the minimum objective function value (OFV). Plasma concentration data were natural logtransformed and evaluated using two-and three-compartment models.
Distributions of IIV were assumed to be log-normal and were described by an exponential error model. The residual error model was described by separate additive terms for Phase 1 and Phase 3 studies and different bioanalytical assay sensitivities. Missing drug concentrations and concentrations below quantifiable limit (477 post-dose samples, representing 7.86% of all data) were excluded from the final analysis.
Investigation of covariate-parameter relationships was based on the range of covariate values in the dataset, scientific interest, mechanistic plausibility and exploratory graphics. Potential covariates were tested in the interim base model univariately and were considered for inclusion in the full model if the parameters were statistically significant and reasonably well estimated (more than 7.9 point [P < 0.005] decrease in OFV for one parameter, and relative standard error [RSE] < 50%). The full model approach with backward deletion was then implemented to retain significant covariates [17] . Insignificant or poorly estimated covariates (less than 10.83 point increase in OFV upon covariate removal, and/or confidence interval [CI] included the null value of the parameter, and/or the parameter was estimated with RSE greater than 50%) were eliminated from the model. For continuous covariates, a power function was utilized. For categorical covariates, the fractional change in the typical parameter value was determined.
The predictive performance of the interim model was evaluated by performing visual predictive checking (VPC) using the Phase 3 data. If the interim model was found to adequately describe the general trend of the data, it was used as a starting point for the final model development with the previously identified covariates included a priori in the starting model. The covariates would be removed if the model failed to converge or a covariance matrix could not be obtained. The structural model was also refined to estimate a separate residual error for the Phase 3 study and to incorporate IIV on the Phase 3 residual error to minimize the influence of anomalous concentrations on the population variance. The final covariate model was developed using the full model approach with backward deletion similar to the interim analysis.
The ability of the final PK model to describe the observed data was investigated using a prediction-corrected predictive check (pcVPC) procedure [18] . Two hundred datasets were simulated using the final model parameters, covariates, sampling times and dosing histories. Both the observed and the simulated concentrations were normalized by the ratio between the median typical population predictions for the specific time bin and the typical population prediction for the observation. The simulated custirsen concentrations with prediction correction were then summarized at the 5th percentile, median and 95th percentile, and the 90th prediction interval around each percentile was calculated. The corresponding percentiles were summarized for observed data for comparison. Nonparametric bootstrap analysis was also performed by generating 157 out of the planned 1000 datasets (reduced due to extremely long computation time) through random sampling with replacement from the original data using the individual as the sampling unit. Population parameters of the final model for each dataset were estimated using NONMEM, and empirical 95% CIs were constructed.
Simulation
A simulation was performed to predict the impact of covariates on custirsen exposure. The final PK model was used to simulate plasma PK profiles for the analysis population with their own set of covariates following a steady-state weekly dose of 640 mg custirsen. The final estimate for the residual error on the Phase 3 study without the associated IIV was used for the simulation to reflect the variability in the observed data but without the inflated variability that was probably caused by error in sample labelling or recording of sampling times. PK parameters, including AUC for the defined interval between doses (AUC tau ; tau = 168 h), C max and concentration at the end of the dosing interval (C tau ), were derived by noncompartmental methods and summarized by covariate categories. Forest plots were created for comparison of simulated parameters among various subpopulations. The median and nonparametric 90% CI for each PK parameter were calculated from each of the 100 simulations by covariate categories [19, 20] . The average of the 100 medians and nonparametric 90% CIs were then obtained within the given covariate categories, which was then normalized by the averaged median of reference category to express the results as the fold-change in the median value and the corresponding 90% CI.
Exploratory PK/pharmacodynamic (PD) analysis
An interim exploratory graphical analysis of potential exposure-response relationships was performed using individual predicted custirsen exposure (C max , C tau and AUC tau ) obtained from the interim population PK model with actual doses administered for respective subjects. For serum clusterin level and prostate-specific antigen (PSA) level, the changes from baseline at the end of the treatment period or to the last sample collected within the treatment period, if the former was not available, was examined. In addition, the maximal change from baseline over the treatment period was explored. Visual examination of the response-exposure scatterplots with the aid of Loess smoothing curve was used to identify trends between the variables; no statistical criterion was employed to assess the significance of the relationship.
Results
Subject characteristics and analysis population
The interim dataset contained custirsen doses ranging from 40 to 640 mg from 105 subjects. During initial model development, nonlinear kinetics-like behaviour was observed for subclinical doses of 40 and 80 mg. Since these dose levels were well below the clinically relevant dosing range and less than 10% of subjects were given these low doses, concentration data from these two dose levels were excluded from all subsequent analysis. Consequently, the interim population PK model of custirsen was developed with 1602 plasma concentrations from 96 subjects with nominal dose levels from 160 to 640 mg. The final model was developed with an expanded dataset containing 5588 concentrations from 631 subjects. The basic distribution of key covariates and number of concentrations by study is described in Table 1 . More extensive demographic and subject covariates data can be found in Table S3 . The majority of the subjects received custirsen at the 640 mg dose level (92%), which was the clinical dose in all ongoing Phase 3 studies. Prostate cancer accounted for 78% of the study population; all other types of cancer accounted for less than 2%. Moreover, all Phase 1 studies enrolled male healthy subjects only; consequently, only 2.7% of the analysis population were females.
Population pharmacokinetics
Population PK model development of custirsen was initiated prior to the completion of the Phase 3 study in an interim analysis. The interim model that best described custirsen PK was a three-compartment linear model with first-order elimination, and was dose-proportional from 160 to 640 mg. The structural model included IIV in total clearance (CL), volume of central and peripheral compartments (V 1 , V 2 ) and inter-compartmental clearance (Q 2 , Q 3 ); correlation between V 1 and Q 2 ; and separate additive residual error for studies with different bioanalytical sensitivity. Gender and baseline creatinine clearance were found to be statistically significant on CL; gender and body mass index (BMI) were predictive of V 1 . Parameter estimates for the interim model and goodnessof-fit plots are shown in Table S4 and Figure S1 , respectively.
The final analysis commenced once the Phase 3 data became available. A VPC using the interim model showed reasonable predictions of the Phase 3 data with 15.8% observed concentrations falling outside of the 90% prediction intervals ( Figure S2 ). Two clusters of anomalous concentrations (66 samples) around 2-h (post-infusion) and 168-h (trough) post-dose were observed, which was most likely attributable to either an incorrect sample collection time or sample labelling error. Since larger variability was expected for the Phase 3 data in comparison with the Phase 1 data, a separate residual error term for the Phase 3 study was included in the structural model. Furthermore, IIV on the Phase 3 residual variance was implemented to allow the residual error magnitude to vary between subjects, hence, effectively assigning larger residual errors for subjects with more variable PK or anomalous data [21] . The robustness of the residual error model was tested by excluding all 66 outliers. While the IIV and the associated residual variability decreased, all major model parameters were nearly identical to those prior to the exclusions, suggesting that the current residual error model adequately minimized the impact of anomalous concentrations on PK parameters. Furthermore, covariates included in the interim model were removed during the final base model development to prevent overparameterization. Table 1 Key demographic data and subject characteristics by study (100) 22 (63) 5 (56) 31 (100) 21 (100) 55 (100) 441 (100) 19 (100) 614 ( 16 (46) 6 (67) 31 (100) 21 (100) 52 (95) 430 (98) 19 (10) 580 (92) Cancer type, n (%) Healthy 499 (9) 785 (14) 90 (2) 228 (4) 260 (5) 1074 (19) 2278 (41) 374 (7) 5588 BMI, body mass index; NSCLC, non-small cell lung carcinoma; PK, pharmacokinetic. 
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The final structural model for custirsen PK resembled the interim structural model, with an additional IIV on the residual variance of the Phase 3 data, and correlations between CL, V 1 , V 2 , and Q 2 . The gender effect on CL and V 1 was tested during covariate model development but was found not to be significant on either parameter. The effect of alkaline phosphatase (ALP) on CL and V 1 was statistically significant. However, the effect was close to zero (CL~ALP = 0.0556, 95% CI = 0.0260-0.0852; V 1~A LP = 0.0780, 95% CI = 0.0406-0.115). Also, increases in ALP would typically be associated with a decline in liver function and hepatic clearance of drugs. Hence, given the small magnitude of effect and lack of physiological plausibility, ALP was removed from the covariate model. The final covariate analysis showed that age, weight and serum creatinine (time-varying) were predictors of CL, and age was a predictor of Q 3 . CL increased with body weight with the power coefficient of 0. Table 2 . The diagnostic plots ( Figure 1 ) indicated that the model adequately described the observed data with no systematic bias in model predictions. Following evaluation by pcVPC, there was overall good agreement for the 5th, median and 95th percentiles of custirsen concentrations between observation and predictions (Figure 2 ), supporting the conclusion that the final PK model provided a good description of the data. The 95th percentile of the observed data was heavily influenced by the cluster of outliers around 168-240 h post-dose, explaining the discrepancy between observations and predictions. A large prediction interval was observed during the early infusion period (time after dose < 1 h), which was likely attributed to the limited number of observations for the sampling period. Furthermore, the bootstrap results were very similar to the NONMEM estimates from the final PK model (Table 2) , indicating the stability of the population PK model and the good precision of parameter estimates.
Results of the simulation
The population PK model was used to simulate the custirsen steady-state profile following 640 mg once-weekly dose in the analysis population. Age, weight and serum creatinine were converted from continuous covariates into clinically relevant categorical covariates. A forest plot depicting foldchanges in custirsen exposure parameters relative to the reference covariate categories is presented in Figure 3 . Relatively small changes (<25%) in AUC tau and C max were observed among the subpopulations. The age effect appeared slightly higher for the >65 years group than the >75 years group but with overlapping 90% prediction intervals, suggesting no statistical difference between the two age groups. Elderly subjects (>65 years) showed 32% higher C tau than younger subjects. Progressive increase in C tau was observed in mildly and moderately/severely renal-impaired subjects at 35% and 56% higher level, respectively, compared with those with normal renal function.
Exploratory PK/PD
Exploratory PK/PD analysis was carried out in subjects with cancer in the interim analysis population. Serum clusterin level and PSA level were available from 63 and 34 patients included in the interim dataset. There was a general trend between downregulation of serum clusterin levels and increasing custirsen exposure (Figure 4 ). This negative correlation was more evident when the maximum change from baseline during the treatment period was examined. Slightly stronger correlations were observed for custirsen C max and AUC tau compared to C tau . The PK/PD exploratory graphical analysis showed no relationship between clinical endpoint of PSA level and custirsen exposure.
Discussion
This is the first meta-analysis to evaluate the population PK of custirsen in cancer patients and healthy subjects. The PK of custirsen following intravenous administration was well described by a three-compartment linear model with firstorder elimination. Furthermore, age, weight and serum creatinine were found to be statistically significant covariates on custirsen clearance. However, the impact of these covariates on custirsen exposure is unlikely to be clinically significant due to the small magnitude of the effects. The plasma PK profile of custirsen was characterized by a rapid decline, up to four to five orders of magnitude in concentrations, within the first 24 h after drug administration, followed by a much slower elimination with quantifiable concentrations up to 1 week after administration. Based on the model-estimated volume and clearance parameters, the derived half-lives for custirsen were 1.68 h, 10.8 h and 8.2 days for the rapid distribution, slow distribution and terminal elimination phases, respectively. This multi-phasic disposition was similar to other secondgeneration antisense oligonucleotides [22, 23] . Based on the model-estimated volumes of distribution, the central compartment most likely represents plasma volume with some degree of plasma protein binding. The distribution of custirsen into the 'shallow' compartment would represent the kidney and liver, which are the major target organs for custirsen tissue distribution based on preclinical data. Custirsen has also been detected at lower levels in the spleen, axillary lymph node, heart and reproductive tissues in preclinical studies, all of which would represent the 'deep' compartment. Using both noncompartmental and compartmental modelling approaches, oligonucleotides exhibited distribution half-lives in hours, while the terminal elimination half-lives ranged from 5 to 52 days. Hence, the plasma PK of oligonucleotides appeared to be relatively conserved within the class and independent of the target mRNA sequence.
The PK structural model and custirsen exposure ranges were largely similar between the interim and final analyses, suggesting that custirsen PK remained consistent across cancer and healthy subject populations. Statistically significant covariates in the final model, including age, weight and time-varying serum creatinine, were all attributes in the derivation of estimated creatinine clearance, which was found to be predictive of custirsen clearance in the interim model. Although these covariates are scientifically plausible, the magnitude of their effects on custirsen exposure was small, and the need for custirsen dosing adjustment in the clinical setting is still to be determined depending on the magnitude of the effect size and therapeutic or toxicity indices. Age-related decline in renal, hepatic and other clearance pathways are commonly associated with decreased clearance of many drugs. In the current analysis, the impact of age on CL would be more pronounced in young adults (28% higher CL for 18-year-old subjects than 66-year-old subjects). However, the current target disease population of cancer, such as mCRPC or lung cancer, would comprise mostly elderly subjects, and subsequently, the age-related decrease in custirsen CL would have limited clinical relevance. Body weight is another common physiological covariate for PK and is frequently incorporated in allometric scaling for many small molecules [24, 25] . The relative influence of weight on custirsen exposures was less than 20% based on simulation; the magnitude of the impact was considered small and was within the expected variability of custirsen PK between subjects. Hence, it is unlikely that the effect of weight would be clinically significant. Interestingly, weight was found to be less important than gender during the interim analysis. Although females were, on average, 25% lighter than males, and the interim PK model estimated 25% and 27% lower CL and V 1 , respectively, in females, weight alone could not account for the observed gender effect. This observed discrepancy in covariate effect could be attributable to the unique disposition characteristics of macromolecule oligonucleotides. The distribution and elimination of oligonucleotides could be influenced by not only body size but also the number of receptors and nuclease enzymes, the latter of which might display suspected gender differences. Due to the small proportion of females in the final analysis population (2.7%) following the inclusion of the Phase 3 prostate population, gender effect was no longer significant in the final model, but warrants re-evaluation once additional Phase 3 data become available in cancer populations with a more balanced gender distribution.
In addition to age and weight, level of serum creatinine, which is a marker for kidney function, was found to be negatively correlated with custirsen clearance. Subjects with high serum creatinine or impaired renal function would have lower custirsen CL and therefore, higher exposure. This finding was consistent with the known renal clearance of oligonucleotides [23] . Monte Carlo simulation using the final analysis population showed moderate increase in custirsen trough levels in mildly (35%) and moderately/severely renal-impaired subjects (56%) relative to subjects with normal renal function. The impact of severe renal impairment could not be assessed in the current analysis due to the lack of subjects in this category.
Finally, the interim PK/PD exploratory graphic analysis showed a correlation between decreases in serum clusterin levels and custirsen exposure. This finding was consistent with the results from the Phase 1 study which demonstrated the presence of custirsen concentrations in the prostate tissue that resulted in dose-dependent inhibitions of clusterin mRNA and protein levels in the prostate cancer cells [13] . The potential correlation between custirsen target tissue concentrations and plasma concentrations as well as the relationship between target protein inhibition in the cancer cells and serum might provide support for serum clusterin as a surrogate biomarker for custirsen activity. However, one confounding factor for the analysis is the potential influence of PD effect by neo-adjuvant hormonal therapy, which could lead to increased clusterin expression in tumour cells that survived androgen ablation therapy [1] . By the same token, the lack of relationship between PSA level and custirsen exposure may result from the confounding 'noise' of the concomitant therapy.
In conclusion, the current meta-analysis incorporating data from Phase 1 to Phase 3 studies successfully developed a population PK model for custirsen in cancer patients and healthy subjects, including subject-specific cofactors contributing to variability in custirsen PK. The PK model can be further refined to assess the influence of cancer types when additional Phase 3 studies are completed.
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